Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Methotrexate for Progressive MS
NCT02644044Phase 1Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Jan 2016
- Primary completion
- Dec 2017
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of methotrexate in multiple sclerosis (MS), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoints: Multiple Sclerosis Functional Composite at 1 year and Safety and tolerability. Status: unknown.
02
Drugs
methotrexate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02644044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02644044.